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Supplemental Fig. 1 
1         ATGGGGAGAGGAGGAGGGGGGTTGGACGTGGGAGGAGGAGGAGAGGGCTCGAGGGACCGT 
1          M  G  R  G  G  G  G  L  D  V  G  G  G  G  E  G  S  R  D  R  
 
61        CTGTCGCGGGACGGGCTGGCCAGCTGGGGCGCGGAGCCTGGAGGAGGAGGCAGCGGCAGC 
21         L  S  R  D  G  L  A  S  W  G  A  E  P  G  G  G  G  S  G  S  
 
121       GGCAGCAGCAGCCCTCCGAGCAGCAGCAGCTGCAGCAGCAGAAACAAGTACCAGCCACAA 
41         G  S  S  S  P  P  S  S  S  S  C  S  S  R  N  K  Y  Q  P  Q  
             
181       AGCGGCTCCTCTGGCCCAAGCAGCCACAGTCCCCCCGCCGCGATGGCGCTGCAAAGCCAG 
61         S  G  S  S  G  P  S  S  H  S  P  P  A  A  M  A  L  Q  S  Q  
              
241       GCGAGCGAGGAAGCAAAGGGGCCCTGGCAGGAGGCAGACCAGGAACAGCAGGAGCCGGTG 
81         A  S  E  E  A  K  G  P  W  Q  E  A  D  Q  E  Q  Q  E  P  V  
 
301       GGTAGCCCAGAGCCGGAGTCTGAGCCGGAGCCTGAGCCCGAGCCCGAGCCCGTGCCAGTG 
101        G  S  P  E  P  E  S  E  P  E  P  E  P  E  P  E  P  V  P  V  
 
361       CCCCCGCCCGAGCCCCAGCCGGAGCCCCAGCCCCTACCGGACCCCGCACCCCTGCCGGAG 
121        P  P  P  E  P  Q  P  E  P  Q  P  L  P  D  P  A  P  L  P  E  
         
421       CTGGAGTTCGAGTCCGAGCGGGTGCACGAACCCGAGCCCACGCCTACGGTAGAGACCCGC 
141        L  E  F  E  S  E  R  V  H  E  P  E  P  T  P  T  V  E  T  R  
      EcoNI/start; MCT1/8 chimera Fw 
481       GGCACCGCGCGCGGCTTCCAGCCTCCCGAAGGTGGCTTCGGCTGGGTGGTGGTGTTCGCT 
161        G  T  A  R  G  F  Q  P  P  E  G  G  F  G  W  V  V  V  F  A  
            Bam HI 
541       GCCACCTGGTGCAACGGCTCCATCTTCGGCATCCATAACTCTGTCGGGATCCTCTACTCC 
181        A  T  W  C  N  G  S  I  F  G  I  H  N  S  V  G  I  L  Y  S  
                                           MCT1/8 chimera Rev                    
601       ATGCTGCTAGAGGAGGAAAAGGAAAAAAATCGCCAAGTGGAGTTCCAAGCAGCATGGGTC 
201        M  L  L  E  E  E  K  E  K  N  R  Q  V  E  F  Q  A  A  W  V  
          EcoNI 
661       GGAGCCCTCGCGATGGGTATGATCTTCTTCTGTTCTCCCATTGTGAGTATATTCACTGAC 
221        G  A  L  A  M  G  M  I  F  F  C  S  P  I  V  S  I  F  T  D  
 
721       CGTTTGGGCTGCCGAATCACAGCAACCGCGGGGGCTGCCGTTGCTTTCATTGGCCTCCAT 
241        R  L  G  C  R  I  T  A  T  A  G  A  A  V  A  F  I  G  L  H  
 
781       ACCAGCTCCTTCACCAGCTCCCTAAGCCTGCGCTACTTCACCTACGGGATTCTCTTTGGT 
261        T  S  S  F  T  S  S  L  S  L  R  Y  F  T  Y  G  I  L  F  G  
 
841       TGTGGCTGTTCCTTCGCCTTTCAGCCATCCCTCGTCATCCTGGGCCACTACTTTCAACGC 
281        C  G  C  S  F  A  F  Q  P  S  L  V  I  L  G  H  Y  F  Q  R  
 
901       CGCCTGGGTCTGGCCAATGGTGTGGTGTCTGCTGGGAGTAGCATTTTCTCCATGTCCTTC 
301        R  L  G  L  A  N  G  V  V  S  A  G  S  S  I  F  S  M  S  F  
 
961       CCCTTCCTCATCAGAATGCTGGGGGATAAGATCAAGCTGGCCCAAACCTTCCAGGTGCTG 
321        P  F  L  I  R  M  L  G  D  K  I  K  L  A  Q  T  F  Q  V  L  
 
1021      AGTACCTTCATGTTTGTTCTTATGCTGCTTTCACTCACCTACCGGCCCCTCCTGCCCAGC 
341        S  T  F  M  F  V  L  M  L  L  S  L  T  Y  R  P  L  L  P  S  
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1081      TCCCAGGACACCCCAAGCAAGAGAGGTGTCCGCACCCTGCACCAGCGCTTTCTGGCTCAG 
361        S  Q  D  T  P  S  K  R  G  V  R  T  L  H  Q  R  F  L  A  Q  
 
 
1141      CTCAGGAAGTACTTCAACATGCGAGTGTTCCGCCAACGCACTTACCGCATCTGGGCCTTC 
381        L  R  K  Y  F  N  M  R  V  F  R  Q  R  T  Y  R  I  W  A  F  
 
1201      GGAATTGCTGCTGCTGCCCTTGGCTACTTTGTTCCCTATGTACACCTGATGAAGTATGTG 
401        G  I  A  A  A  A  L  G  Y  F  V  P  Y  V  H  L  M  K  Y  V  
 
1261      GAGGAGGAGTTCTCAGAAATCAAGGAGACCTGGGTGCTCTTGGTGTGTATTGGGGCTACC 
421        E  E  E  F  S  E  I  K  E  T  W  V  L  L  V  C  I  G  A  T  
 
1321      TCAGGCCTTGGGCGTCTTGTGTCAGGCCACATCAGTGACTCCATCCCTGGACTTAAGAAG 
441        S  G  L  G  R  L  V  S  G  H  I  S  D  S  I  P  G  L  K  K  
 
1381      ATCTACTTGCAGGTCCTTTCCTTCCTGCTCCTGGGCCTGATGTCCATGATGATTCCCCTG 
461        I  Y  L  Q  V  L  S  F  L  L  L  G  L  M  S  M  M  I  P  L  
 
1441      TGCCGGGACTTCGGGGGCCTTATCGTCGTCTGTCTTTTCCTGGGCCTTTGCGATGGCTTC 
481        C  R  D  F  G  G  L  I  V  V  C  L  F  L  G  L  C  D  G  F  
 
1501      TTCATCACCATCATGGCCCCCATTGCATTTGAGCTGGTGGGCCCAATGCAGGCCTCACAG 
501        F  I  T  I  M  A  P  I  A  F  E  L  V  G  P  M  Q  A  S  Q  
 
1561      GCCATTGGCTACCTCCTGGGCATGATGGCCCTGCCAATGATTGCTGGGCCCCCCATTGCA 
521        A  I  G  Y  L  L  G  M  M  A  L  P  M  I  A  G  P  P  I  A  
 
1621      GGCCTACTCCGCAACTGTTTTGGGGACTACCATGTGGCCTTCTACTTTGCCGGTGTGCCC 
541        G  L  L  R  N  C  F  G  D  Y  H  V  A  F  Y  F  A  G  V  P  
 
1681      CCCATCATCGGGGCTGTAATCCTCTTCTTCGTCCCTCTGATGCATCAAAGGATGTTCAAG 
561        P  I  I  G  A  V  I  L  F  F  V  P  L  M  H  Q  R  M  F  K  
 
1741      AAAGAGCAGAGAGATTCCAGCAAGGATAAGATGTTGGCCCCTGACCCAGACCCCAATGGG 
581        K  E  Q  R  D  S  S  K  D  K  M  L  A  P  D  P  D  P  N  G  
 
1801      GAGCTACTGCCGGGCTCCCCCAACCCTGAGGAACCAATCTAA 
601        E  L  L  P  G  S  P  N  P  E  E  P  I  *  
 
cDNA sequence of coding region of the hMCT8 construct that was used for the generation of all described 
mutant and tagged MCT8 constructs. This construct only contains the coding sequence of the short MCT8 
isoform starting at Met75. The sequence encoding the unique part of the long MCT8 isoform is depicted 
in light grey and is shown to clarify the amino acid numbering. Locations of the introduced mutations are 
in bold, underlined and highlighted in grey. The Bam HI and Eco NI restriction sites are displayed in italic 
and underlined font, the locations of the forward and reverse primer used in the generation of the MCT1/8 
chimera are highlighted in green and the splice sites are boxed.  
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Supplemental Figure 2 
 
 
(A) Immunoblot of total cell lysates derived from COS-1 cells transiently expressing WT MCT8 
incubated with increasing concentrations of the Ca2+ / Mg2+ chelator EDTA for 30 minutes before the 
addition of LDS loading buffer, containing 10 mM DTT. Note that MCT8 is expressed as monomer (~55 
kDa), homo-dimer (~110 kDa) and homo-oligomer (~170 kDa). Increasing concentrations of EDTA did 
not affect MCT8 oligomerization. MCT8 was detected using the N-terminal MCT8 antibody (3353) and 
GAPDH was used as a loading control. (B) Immunoblot on total lysates of COS-1 cells transiently 
expressing WT MCT8 incubated with increasing concentrations DTT in LDS for 10 minutes at 70°C prior 
to separation.  Increasing concentrations of DTT did not affect MCT8 oligomerization. MCT8 was 
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detected using the N-terminal MCT8 antibody (3353) and GAPDH was used as a loading control. (C) 
Immublot on total lysates derived from skin fibroblasts obtained from a healthy subject, using the N-
terminal MCT8 antibody (3353) and GAPDH as a loading control. Note that endogenously expressed 
MCT8 is also detected as a monomer, homo-dimer and putative homo-oligomer. Abbreviations: EDTA, 
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Supplemental Figure 3 
 
Representative blots (N=3) of co-IP studies on lysates derived from COS-1 cells transiently expressing 
MCT10 alone (lane 2), or in combination with Flag-MCT8 (lane3). Blots were simultaneously stained 
with mouse M2 anti-Flag and rabbit anti-MCT10 antiserum (designated 1758). MCT10 could not be 
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Supplemental Figure 4 
 
Representative immunoblot of lysates from COS-1 cells transfected with WT MCT8 or the MCT8M75A 
mutant (N=2), performed as described in Fig. 2D. Note, that no signal was obtained upon inactivation of 
the natural translation start site (Met75) using antibodies directed against the N-terminus of MCT8. 
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Representative Western Blot analyses on total lysates and the cell surface fraction derived from COS-1 
cells transfected with pcDNA3 EV, WT MCT8 or the MCT874-230 mutant. The input sample comprises 5% 
of the clarified lysate from which the presented surface fraction was derived. MCT8 detection was 
performed with the N-terminal MCT8 antibody (3353) and visualized with IRDye680 goat anti-rabbit 
secondary antibody. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as loading control. 
Note the absence of GAPDH in the cell surface samples, demonstrating the purity of the cell surface 
fraction. Whereas bands corresponding to WT monomer and dimer were detected in the surface fraction, 
no bands corresponding to the MCT874-230 mutant MCT8 were observed, confirming the confocal data 
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Supplemental Figure 6 
 
Representative blots of co-IP studies on lysates derived from COS-1 cells transiently expressing Flag-
MCT8 (75 ng cDNA, lane 2), Myc-MCT8 (75 ng cDNA, lane 3) alone, or combined (lane 4), and COS-1 
cells co-expressing Flag-MCT8 and Myc-MCT8 and increasing amounts of the MCT875-230 mutant 
construct (lane 5-8). Blots were subsequently stained with mouse M2 anti-Flag antibody and rabbit anti-
Myc antibody, stripped and stained with rabbit anti-MCT8 antibody. Input and IP samples were run on 
separate gels (boxed). Note that increasing concentrations of MCT875-230 reduced the amount of Myc-
MCT8 detected in the IP samples, indicating that MCT875-230 may compete with the formation of WT 
Flag-MCT8/Myc-MCT8 interactions. Please note the decrease in Flag-MCT8 signal on the input blot with 
increasing concentrations of MCT875-230 (B) Quantification by densitometry (using ImageJ) of the Myc-
MCT8 and MCT875-230 protein levels in the IP samples shown in (A), expressed relative to the intensity of 
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the Flag-MCT8 band in the same IP sample. (C) Parallel T3 uptake studies (30 minutes at 37 C) in COS-1 
cells co-expressing equal amounts of WT Flag-MCT8 and Myc-MCT8 as in (A), increasing amounts of 
the MCT875-230 mutant, and a fixed amount of CRYM (250 ng). The results of the uptake studies are 
presented as means ± SEM (n=3). There are no statistically significant differences as analyzed with a 1-
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Supplemental Table 1                      





























Rabbit (p) ATLAS 
(HPA003353) 
1:20000 1:1000 AB_1079343 




Rabbit (p) Personal AB 
(19) 
1:1000 1:500 AB_2661880 




Rabbit (p) Personal AB 
(19) 
1:1000  AB_2661879 
GAPDH  GAPDH Mouse (m) Millipore  
(Mab 374) 
1:20000  AB_2107445 
ZO1  ZO1 Mouse (m) Thermo Fisher 
(33-9100) 
1:1000 1:1000 AB_2533147 
Flag Flag epitope Flag-M2 Mouse (m) Sigma (C3956) 1:1000  AB_439680 
Myc Myc epitope Myc Rabbit (m) Sigma (F1804) 1:1000  AB_262044 
Mouse 
IgG 
 IRDye680 Goat LI-COR (926-
68020) 
1:20000  AB_10706161 
Rabbit 
IgG 
 IRDye800 Goat LI-COR (926-
32211) 
1:20000  AB_621843 
Rabbit 
IgG 
 Alexa 488 Goat Thermo Fisher 
(A11008) 
 1:1000 AB_143165 
Mouse 
IgG 
 Alexa 633 Goat Thermo Fisher 
(A21050) 
 1:1000 AB_2535718 
GAPDH: glyceraldehyde-3-phosphate dehydrogenase; ZO-1: zona occludens 1; P: polyclonal antibody; M: 
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Supplemental Table 2 
Overview of primers 






































Restriction sites within the primers are underlined; the locations of introduced mutations are depicted in bold. 
 
 
